secwatch.observer — SEC 8-K summary
======================================

Issuer:     X4 Pharmaceuticals, Inc (XFOR)
CIK:        0001501697
Form:       8-K
Filed at:   2023-05-04T23:59:59+00:00
Accession:  0001628280-23-015415
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

X4 Pharma Q1 net loss $24.0M; cash $94.4M into Q2 2024; mavorixafor NDA on track
--------------------------------------------------------------------------------

- Net loss of $24.0M in Q1 2023 vs $22.0M in Q1 2022; R&D expenses $22.1M including $5.0M milestone accrual.
- Cash, equivalents & restricted cash $94.4M as of March 31, 2023; sufficient to fund operations into Q2 2024.
- U.S. NDA submission for mavorixafor in WHIM syndrome on track for early second half of 2023.
- Phase 3 WHIM trial infection data to be presented at May 16 webinar and May 21 CIS oral presentation.
- Phase 2 chronic neutropenia trial data and regulatory path clarity expected in Q2/Q3 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1501697/000162828023015415/0001628280-23-015415-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1501697/000162828023015415/xfor-20230504.htm
  HTML page:      https://secwatch.observer/filing/0001628280-23-015415

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer